HC Wainwright Issues Positive Forecast for Innoviva Earnings

Innoviva, Inc. (NASDAQ:INVA) – Research analysts at HC Wainwright boosted their FY2026 earnings estimates for shares of Innoviva in a note issued to investors on Monday, August 10th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of $2.30 per share for the year, up from their previous estimate of $2.20. HC Wainwright currently has a “Buy” rating and a $46.00 target price on the stock. The consensus estimate for Innoviva’s current full-year earnings is $2.20 per share. HC Wainwright also issued estimates for Innoviva’s Q2 2027 earnings at $0.62 EPS and FY2027 earnings at $2.37 EPS.

INVA has been the subject of a number of other reports. BTIG Research reaffirmed a “buy” rating and set a $42.00 price target on shares of Innoviva in a report on Monday, June 22nd. Zacks Research downgraded Innoviva from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Cantor Fitzgerald cut their target price on Innoviva from $36.00 to $34.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Wall Street Zen cut Innoviva from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Innoviva in a report on Wednesday, June 24th. Four investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $34.75.

Innoviva Stock Performance

NASDAQ:INVA opened at $20.75 on Wednesday. The firm has a market capitalization of $1.53 billion, a PE ratio of 5.06 and a beta of 0.35. The business’s fifty day moving average price is $22.02 and its 200 day moving average price is $22.32. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.01 and a quick ratio of 15.18. Innoviva has a 12 month low of $16.52 and a 12 month high of $25.15.

Hedge Funds Weigh In On Innoviva

Several large investors have recently bought and sold shares of INVA. Vanguard Group Inc. increased its position in shares of Innoviva by 11.6% during the fourth quarter. Vanguard Group Inc. now owns 7,917,103 shares of the biotechnology company’s stock worth $158,263,000 after purchasing an additional 819,757 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Innoviva in the 2nd quarter valued at about $77,562,000. Dimensional Fund Advisors LP boosted its position in shares of Innoviva by 1.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,436,427 shares of the biotechnology company’s stock valued at $103,366,000 after purchasing an additional 76,026 shares during the period. State Street Corp grew its stake in Innoviva by 9.4% during the 4th quarter. State Street Corp now owns 2,796,820 shares of the biotechnology company’s stock worth $55,908,000 after buying an additional 239,848 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in Innoviva by 38.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,358,633 shares of the biotechnology company’s stock worth $43,045,000 after buying an additional 650,151 shares during the last quarter. Institutional investors and hedge funds own 99.12% of the company’s stock.

About Innoviva

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.